
Hamlet BioPharma AB
HAMLET | SPGR
Overview
Corporate Details
- ISIN(s):
- SE0015661145 (+2 more)
- LEI:
- 549300HJV2LJY4CDBR64
- Country:
- Sweden
- Address:
- Klinikgatan 32, 222 42 LUND
- Website:
- https://hamletbiopharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Hamlet BioPharma AB is a clinical-stage pharmaceutical company developing novel therapies for cancer and infections. Its lead oncology candidate, Alpha1H, is a tumor-killing protein-lipid complex designed to selectively target and eliminate tumor cells while sparing healthy tissue. Alpha1H has successfully completed Phase II trials for bladder cancer, demonstrating significant tumor reduction and immune system activation. The company is also advancing immunotherapy as an alternative to antibiotics. Its IL-1 inhibitor, anakinra, has completed Phase II studies showing positive results in treating patients with recurrent urinary tract infections and Bladder Pain Syndrome (interstitial cystitis). Hamlet BioPharma's pipeline focuses on creating highly specific treatments with improved safety profiles for significant unmet medical needs.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Hamlet BioPharma AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
No filings match the current criteria. |
Automate Your Workflow. Get a real-time feed of all Hamlet BioPharma AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Hamlet BioPharma AB via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |